Smithers has developed and validated over 100 PK and ADA assays for therapeutic monoclonal and polyclonal antibodies. Smithers also currently supports many cell-based neutralizing antibody assays in phase III clinical trials, supporting monoclonal/polyclonal antibody development from discovery through phase IV.